摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N2-benzyl thiosemicarbazide | 7449-43-6

中文名称
——
中文别名
——
英文名称
N2-benzyl thiosemicarbazide
英文别名
1-benzyl-thiosemicarbazide;1-Benzyl-thiosemicarbazid;N1-Benzyl-thiosemicarbazid;(Benzylamino)thiourea
N2-benzyl thiosemicarbazide化学式
CAS
7449-43-6
化学式
C8H11N3S
mdl
——
分子量
181.261
InChiKey
FMKMPJXDAVADRQ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.8
  • 重原子数:
    12
  • 可旋转键数:
    3
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.12
  • 拓扑面积:
    82.2
  • 氢给体数:
    3
  • 氢受体数:
    2

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Reactivity of 2-substituted hydrazinecarbothioamides towards tetracyanoethylene and convenient synthesis of (5-amino-2-diazenylthiazolylmethylene)malononitrile derivatives
    作者:Alaa A. Hassan、Nasr K. Mohamed、Kamal M. A. El-Shaieb、Hendawy N. Tawfeek、Stefan Bräse、Martin Nieger
    DOI:10.24820/ark.5550190.p009.872
    日期:——
    Alaa A. Hassan,* Nasr K. Mohamed, Kamal M. A. El-Shaieb, Hendawy N. Tawfeek, Stefan Bräse, and Martin Nieger c a Chemistry Department, Faculty of Science, Minia University, 61519 El-Minia, Egypt b Institute of Organic Chemistry, Karlsruhe Institute of Technology, Fritz-Haber-Weg 6, 76131 Karlsruhe, Germany c Laboratory of Inorganic Chemistry, Department of Chemistry, University of Helsinki P.O. Box
    Alaa A. Hassan、* Nasr K. Mohamed、Kamal MA El-Shaieb、Hendawy N. Tawfeek、Stefan Bräse 和 Martin Nieger ca 化学系,米尼亚大学理学院,61519 El-Minia,埃及 b 有机化学研究所, 卡尔斯鲁厄理工学院, Fritz-Haber-Weg 6, 76131 Karlsruhe, Germany c Laboratory of Inorganic Chemistry, Department, Helsinki, University of Helsinki PO Box 55 (AI Virtasen aukio 1), 00014 Helsinki, Finland 电子邮件:alaahassan2001@ mu.edu.eg
  • Reverse-turn mimetics and method relating thereto
    申请人:Moon Hwan Sung
    公开号:US20060084655A1
    公开(公告)日:2006-04-20
    Conformationally constrained compounds that mimic the secondary structure of reverse-turn regions of biologically active peptides and proteins are disclosed. Such reverse-turn mimetic structures have utility over a wide range of fields, including use as diagnostic and therapeutic agents. Libraries containing the reverse-turn mimetic structures of this invention are also disclosed as well as methods for screening the same to identify biologically active members. The invention also relates to the use of such compounds for inhibiting or treating disorders modulated by Wnt-signaling pathway, such as cancer, especially colorectal cancer, restenosis associated with angioplasty, polycystic kidney disease, aberrant angiogenesis disease, rheumatoid arthritis disease, tuberous sclerosis complex, Alzheimer's disease, excess hair growth or loss, or ulcerative colitis.
    本发明揭示了限制构象的化合物,其模拟具有生物活性的肽和蛋白质的反转区域的二级结构。这种反转模拟结构在广泛的领域中具有实用性,包括用作诊断和治疗剂。本发明还揭示了包含此类反转模拟结构的库,以及筛选这些库以识别具有生物活性成员的方法。本发明还涉及使用这种化合物来抑制或治疗Wnt信号通路调节的疾病,如癌症,特别是结直肠癌,与血管成形术相关的再狭窄,多囊肾病,异常血管生成疾病,类风湿性关节炎疾病,结节性硬化症,阿尔茨海默病,过多或过少的毛发生长或溃疡性结肠炎。
  • Prostaglandins
    申请人:NATIONAL RESEARCH DEVELOPMENT CORPORATION
    公开号:EP0043292A2
    公开(公告)日:1982-01-06
    Novel compounds have a formula (I) wherein represents a bicyclo (2,2,1) hept-2Z-ene, bicyclo (2,2,1) heptane, 7-oxabicyclo (2,2,1) hept-2Z-ene, 7-oxabicyclo (2,2,1) heptane, bicyclo (2,2,2) oct-2Z-ene or bicyclo (2,2,2) octane substituted at the 5-position by the group R1 and at the 6-position by the group C(R2)=NR, a 6,6-dimethyl-bicyclo (3,1,1) heptane substituted at the 5- position by the group R' and at the 6-position by the group C(R2)=NR or at the 5-position by the group C(R2)=NR and at the 6-position by the group R1, a cyclohex-1-ene or cyclohexane substituted at the 4-position by the group R1 and at the 5-position by the group C(R2)=NR, or a 1-hydroxycyclopentane substituted at the 2-position by the group R1 and at the 2-position by the group C(R2)=NR, R1 is a 6-carboxyhex-2-enyl group or a modification thereof as defined herein, R2 is hydrogen, an aliphatic hydrocarbon group or an aliphatic hydrocarbon group substituted directly or through an oxygen or sulphur atom by an aromatic group, and R is a group -OR3, -OR4, -A-R3 or -N=R5 in which A is -NH-, -NH.CO-, -NH.CO.CH2N(R6)-, -NH.SO2-, -NH.CO.NH or -NH.CS.NH- and wherein R3 is an aliphatic hydrocarbon group, an aromatic group or an aliphatic hydrocarbon group substituted directly or through an oxygen or sulphur atom by an aromatic group, R4 is an aliphatic hydrocarbon group which is substituted through an oxygen atom by an aliphatic hydrocarbon group which is itself substituted by an aromatic group, R5 is an aliphatic hydrocarbon group, an aromatic group or an aliphatic hydrocarbon group substituted directly or through an oxygen or sulphur atom by an aromatic group, and R6 is hydrogen, an aliphatic hydrocarbon group, an aromatic group or an aliphatic hydrocarbon group substituted directly or through an oxygen or sulphur atom by an aromatic group, with the proviso that when R is a group -OR3, -NH.COR3 or-NH.CO.NHR3 then excludes bicyclo (2,2,1) hept-2Z-enes and bicyclo (2,2,1) heptanes. The compounds are of value for use in phar. maceutical compositions particularly in the context of the inhibition of thromboxane activity.
    新型化合物具有式 (I) 其中 代表在 5 位被基团 R1 取代、在 6 位被基团 C(R2)=NR 取代的双环(2,2,1)庚-2Z-烯、双环(2,2,1)庚烷、7-氧杂双环(2,2,1)庚烷、双环(2,2,2)辛-2Z-烯或双环(2,2,2)辛烷、在 5 位被基团 R'取代、在 6 位被基团 C(R2)=NR 取代的 6,6-二甲基双环(3,1,1)庚烷,或在 5 位被基团 C(R2)=NR 取代、在 6 位被基团 R1 取代的 6,6-二甲基双环(3,1,1)庚烷、在 4 位被基团 R1 取代且在 5 位被基团 C(R2)=NR 取代的环己-1-烯或环己烷,或在 2 位被基团 R1 取代且在 2 位被基团 C(R2)=NR 取代的 1-羟基环戊烷、R1 是本文定义的 6-羧基己-2-烯基或其改性物,R2 是氢、脂肪族烃基或直接或通过氧原子或硫原子被芳香族基取代的脂肪族烃基,R 是基团-OR3、-OR4、-A-R3 或-N=R5,其中 A 是-NH-、-NH.CO-、-NH.CO.CH2N(R6)-、-NH.SO2-、-NH.CO.NH 或 -NH.CS.其中 R3 是直接或通过氧原子或硫原子被芳香基团取代的脂肪烃基团、芳香基团或脂肪烃基团,R4 是通过氧原子被本身被芳香基团取代的脂肪烃基团,R5 是脂肪烃基团、R6是氢、脂肪族烃基、芳香族基团或直接或通过氧原子或硫原子被芳香族基团取代的脂肪族烃基,但当R是-OR3、-NH.COR3或-NH.CO.NHR3,则 不包括双环(2,2,1)庚-2Z-烯和双环(2,2,1)庚烷。这些化合物在医药组合物中具有使用价值,特别是在抑制血栓素活性方面。
  • Prostaglandin intermediates
    申请人:NATIONAL RESEARCH DEVELOPMENT CORPORATION
    公开号:EP0111955A1
    公开(公告)日:1984-06-27
    Novel compounds have a formula (I) wherein represents a bicyclo [2,2,1] hept-2Z-ene, bicyclo [2,2,1] heptane, 7-oxabicyclo [2,2,1] hept-2Z-ene, 7-oxabicyclo [2,2,1] heptane, bicyclo [2,2,2] oct-2Z-ene or bicyclo [2,2,2] octane substituted at the 5-position by the group R' and at the 6-position by the group C(R2)=NR, a 6,6-dimethyl-bicyclo [3,1,1] heptane substituted at the 5-position by the group R' and at the 6-position by the group C(R2)=NR or at the 5-position by the group C(R2)=NR and at the 6-position by the group R', a cyclohex-1-ene or cyclohexane substituted at the 4-position by the group R1 and at the 5-position by the group C(R2)=NR, or a 1-hydroxycyclopentane substituted at the 2-position by the group R1 and at the 2-position by the group C(R2)=NR, R1 is a 6-carboxyhex-2-enyl group or a modification thereof as defined herein, R2 is hydrogen, an aliphatic hydrocarbon group or an aliphatic hydrocarbon group substituted directly or through an oxygen or sulphur atom by an aromatic group, and R is a group -OR3, -OR4, -A-R3 or -N=R5 in which A is -NH-, -CH.CO-, -NH.CO.CH2N(R6)-, -NH.S02-, -NH.CO.NH or -NH.CS.NH-and wherein R3 is an aliphatic hydrocarbon group, an aromatic group or an aliphatic hydrocarbon group substituted directly or through an oxygen or sulphur atom by an aromatic group, R4 is an aliphatic hydrocarbon group which is substituted through an oxygen atom by an aliphatic hydrocarbon group which is itself substituted by an aromatic group, R5 is an aliphatic hydrocarbon group, an aromatic group or an aliphatic hydrocarbon group substituted directly or through an oxygen or sulphur atom by an aromatic group, and R6 is hydrogen, an aliphatic hydrocarbon group, an aromatic group or an aliphatic hydrocarbon group substituted directly or through an oxygen or sulphur atom by an aromatic group, with the proviso that when R is a group -OR3, - NH.COR3 or -NH.CO.NHR3 then excludes bicyclo [2,2,1] hept-2Z-enes and bicyclo [2,2,1] heptanes. The compounds are of value for use in pharmaceutical compositions particularly in the context of the inhibition of thromboxane activity.
    新型化合物具有式 (I) 其中 代表在 5 位被基团 R'取代、在 6 位被基团 C(R2)=NR.取代的双环[2,2,1]庚-2Z-烯、双环[2,2,1]庚烷、7-氧杂双环[2,2,1]庚烷、双环[2,2,2]辛-2Z-烯或双环[2,2,2]辛烷、在 5 位被基团 R'取代、在 6 位被基团 C(R2)=NR 取代的 6,6-二甲基双环[3,1,1]庚烷,或在 5 位被基团 C(R2)=NR 取代、在 6 位被基团 R'取代的 6,6-二甲基双环[3,1,1]庚烷、在 4 位被基团 R1 取代、在 5 位被基团 C(R2)=NR 取代的环己-1-烯或环己烷,或在 2 位被基团 R1 取代、在 2 位被基团 C(R2)=NR 取代的 1-羟基环戊烷、R1 是本文定义的 6-羧基己-2-烯基或其改性物,R2 是氢、脂肪族烃基或直接或通过氧原子或硫原子被芳香族基取代的脂肪族烃基,R 是基团-OR3、-OR4、-A-R3 或-N=R5,其中 A 是-NH-、-CH.CO-、-NH.CO.CH2N(R6)-、-NH.S02-、-NH.CO.NH 或 -NH.CS.其中 R3 是脂肪族烃基、芳香族基团或直接或通过氧原子或硫原子被芳香族基团取代的脂肪族烃基;R4 是通过氧原子被脂肪族烃基取代的脂肪族烃基,该脂肪族烃基本身被芳香族基团取代;R5 是脂肪族烃基、R6是氢、脂肪族烃基、芳香族基团或直接或通过氧原子或硫原子被芳香族基团取代的脂肪族烃基,但当R是-OR3、-NH.COR3或-NH.CO.NHR3,则 不包括双环[2,2,1]庚-2Z-烯和双环[2,2,1]庚烷。这些化合物具有药物组合物的使用价值,特别是在抑制血栓素活性方面。
  • Non-toxic corrosion-protection pigments based on manganese
    申请人:——
    公开号:US20040011252A1
    公开(公告)日:2004-01-22
    Corrosion-inhibiting pigments based on manganese are described that contain a trivalent or tetravalent manganese/valence stabilizer complex. An inorganic or organic material is used to stabilize the trivalent or tetravalent manganese ion to form a compound that is sparingly soluble, exhibits low solubility, or is insoluble in water, depending upon the intended usage. Specific stabilizers are chosen to control the release rate of trivalent or tetravalent manganese during exposure to water and to tailor the compatibility of the powder when used as a pigment in a chosen binder system. Stabilizers may also modify the processing and handling characteristics of the formed powders. Manganese/valence stabilizer combinations are chosen based on the well-founded principles of manganese coordination chemistry. Many manganese-valence stabilizer combinations are presented that can equal the performance of conventional hexavalent chromium or tetravalent lead systems. It is emphasized that this abstract is provided to comply with the rules requiring an abstract which will allow a searcher or other reader to quickly ascertain the subject matter of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the claims.
    以锰为基础的缓蚀颜料含有三价或四价锰/价稳定剂复合物。一种无机或有机材料可用于稳定三价或四价锰离子,从而形成一种可少量溶解、溶解度低或不溶于水的化合物,具体取决于预期用途。选择特定的稳定剂是为了控制三价锰或四价锰在遇水时的释放率,并调整粉末在所选粘合剂体系中用作颜料时的相容性。稳定剂还可以改变成型粉末的加工和处理特性。锰/价稳定剂组合的选择是基于锰配位化学的基本原理。文中介绍了许多锰价稳定剂组合,其性能与传统的六价铬或四价铅体系相当。需要强调的是,提供本摘要是为了符合要求提供摘要的规则,以便检索者或其他读者快速确定技术公开的主题。提交本摘要的前提是,本摘要不用于解释或限制权利要求的范围或含义。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐